Journal
NEUROENDOCRINOLOGY
Volume 103, Issue 1, Pages 59-65Publisher
KARGER
DOI: 10.1159/000381644
Keywords
Pegvisomant; Acromegaly; Monotherapy; Combination therapy; Long-acting somatostatin analogues; Quality of life; Side effects
Categories
Funding
- Ipsen
- Pfizer
- Novartis
Ask authors/readers for more resources
Historically, medical treatment of acromegaly has mainly been used as an adjuvant therapy after surgery. In the last decades, an increased range of medical therapy options has been available. Somatostatin analogues have become the cornerstones of medical treatment in acromegaly and are even seen as a primary treatment in a selected group of acromegaly patients. The most recent medical treatment available for acromegaly patients is pegvisomant, a growth hormone receptor antagonist. To date, it is the most effective medical treatment, but it is costly. Pegvisomant is used as monotherapy and combined with somatostatin analogues. In this article, we review clinical studies and cohorts that have documented the efficacy of pegvisomant monotherapy and combined therapy and give a concise overview of associated side effects. (C) 2016 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available